Regarding the outcomes assessed, six studies evaluated the incidence of MACE (such as myocardial infarction, stroke, and cardiovascular death), two studies focused on the reduction of inflammatory biomarkers such as hs-CRP and IL-6, and four reported on adverse events, particularly mild gastrointestinal effects. The gene discussed is IL6; the disease is stroke disorder.